Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials
…March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2A. CMT is a degenerative neuromuscular disease that kills the long, or peripheral, nerves to…
CMT2C: Share Your Story
…future of CMT2C clinical research. CMTA’s Commitment to Patient-Centered Research CMTA remains committed to supporting patient-centered research, and along with our CMTA-STAR Alliance Partner Actio Biosciences, we are excited to…
Voice_of_the_Patient_Report_8-19-2019
…PMP22 (CMT1A/HNPP), GJB1 (CMT1X), MFN2 (CMT2A), and MPZ (CMT1B). There are rarer forms of CMT that are autosomal recessive demyelinating motor and sensory neuropathies that include several genes categorized as…
CMT-and-Genetic-Testing-Why-Is-It-Important
…type of CMT is autosomal dominant demyelinating CMT, or CMT1. The most common genes in this type are PMP22 (CMT1A) and MPV (CMT1B). CMT2 refers to axonal CMT with autosomal…
CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of a…
The 2020 Winter CMTA Report
…see in the world of CMT. Be the Change: A Message from CEO Amy Gray Swimming Uphill with Jamal Hill CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT…
Double Your Year-End Gift – Help Create a Future Without CMT!
…walker behind. Zolana, diagnosed at 7, dreams of becoming an artist and supports CMTA’s groundbreaking research to make a world free of CMT pain possible. By making your year-end donation…
Jonah Berger, CMTA Youth Programs Manager
How to Talk About CMT Jonah Berger It is one thing to travel through this life with the unstable feet and uncertain balance of CMT. It is another thing altogether…
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
…designation (RPDD) designation from the FDA for ABS-0871, a TRPV4 inhibitor for treating CMT2C. This achievement represents a crucial step forward for CMT2C patients and the CMT community. “We are…
CMTA Appoints David Skarinsky to its Therapy Expert Board
…by Novartis), focusing on neuromuscular disease and CMT1A drug development. CMTA’s TEB, comprising top experts in CMT, provides scientific input, evaluates ongoing or proposed CMTA-funded research projects, and guides the…